News - Thu, 04/24/2025 - 08:45
Dr. Bùi Quang Lộc presents a report on the treatment of advanced biliary cancer at the 2025 Annual Scientific Conference of Chợ Rẫy Hospital
Last update 05/02/2025 - 08:47
The 2025 Annual Scientific Conference of Chợ Rẫy Hospital is considered one of the largest academic events of the year for the Vietnamese medical community, with the participation of more than 1,000 delegates from both domestic and international institutions. With over 400 scientific reports spanning various fields such as Internal Medicine, Surgery, Paraclinical Sciences, Nursing, and more, this event is not only a platform for professional exchange but also an opportunity to promote research activities and practical applications in public healthcare.
As part of the event, Dr. Bùi Quang Lộc — Head of the Oncology Unit at ƽ — participated and presented a scientific report in the session on Hepatobiliary Surgery - Liver Cancer, with the topic: “Update on the treatment of advanced biliary cancer in 2025: A clinical case review and a literature perspective.”
Biliary cancer is a rare type of cancer, difficult to detect early, and often diagnosed at an advanced stage. At the time of diagnosis, 60-65% of patients no longer have curative treatment options. In the advanced stages, patients rarely have a chance for surgery, and the treatment goal focuses on extending survival, managing symptoms, and improving the patient’s quality of life.
Dr. Bùi Quang Lộc's report emphasized the latest groundbreaking advancements in the treatment of advanced biliary cancer through large-scale studies like TOPAZ-1 and KEYNOTE-966. These studies showed that combining standard chemotherapy with immunotherapy significantly enhances treatment efficacy compared to chemotherapy alone.
The presentation also provided examples of cases currently being monitored and treated by Dr. Lộc and his team. One such case involves a biliary cancer patient with metastasis to multiple organs. After 10 months of treatment with targeted therapy combined with chemotherapy, the tumor size reduced from 11x11cm to 5.7x2.8cm, and the patient is now under stable observation.
Dr. Bùi Quang Lộc’s presence and expertise at the conference is a testament to the continuous efforts of the medical team at ƽ in updating the latest medical knowledge, fostering academic connections, and applying them effectively in clinical practice. This contributes to providing more opportunities for survival and improving the quality of life for cancer patients in general, and biliary cancer patients in particular.
